Expression of insulin-like growth factor receptor (IGF-1R), c-Fos, and c-Jun in uveal melanoma: An immunohistochemical study

Current Eye Research

Volumn 31, Issue 10, 2006, Pages 875-883

  Mallikarjuna, Kandalam ^a   Pushparaj, Vaijayanthi ^a   Biswas, Jyotirmay ^a   Krishnakumar, Subramanian ^a  

^a VISION RESEARCH FOUNDATION   (India)

Author keywords

c Fos; c Jun; Choroidal melanoma; IGF 1R; Immunohistochemistry; Metastasis

Indexed keywords

PROTEIN C FOS; PROTEIN C JUN; SOMATOMEDIN C RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SIZE; CHOROID MELANOMA; CLINICAL ARTICLE; CORRELATION COEFFICIENT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MALE; MITOSIS INDEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; TUMOR ASSOCIATED LEUKOCYTE; UVEA MELANOMA;

ADOLESCENT; ADULT; AGED; CHILD; CHOROID NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; RECEPTOR, IGF TYPE 1; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 33750047466     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.1080/02713680600878790     Document Type: Article

References (26)

1. Egan KM, Seddon JM, Glynn RJ, et al. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol. 1988;32(4):239-251.
2. Kath R, Hayungs J, Bornfeld N, et al. Prognosis and treatment of disseminated uveal melanoma. Cancer, 1993;72:2219-2213.
3. Tang CK, Gong XQ, Moscatello DK, et al. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res. 2000;60(11):3081-3087.
4. Pietrzkowski Z, Lammers R, Carpenter G, et al. Constitutive expression of insulin-like growth factor 1 and insulin-like growth factor 1 receptor abrogates all requirements for exogenous growth factors. Cell Growth Differ. 1992;3(4):199-205.
5. Nathanson SD, Slater R, Debruyn D, et al. Her-2/neu expression in primary breast cancer with sentinel lymph node metastasis. Ann Surg Oncol. 2006;13(2):205-213.
6. Song H, Sondak VK, Barber DL, et al. Modulation of Janus kinase 2 by cisplatin in cancer cells. Int J Oncol. 2004;24(4):1017-1026.
7. Niu G, Bowman T, Huang M, et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene. 2002;21(46):7001-7010.
8. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev. 2000;21(3):215-244.
9. Pollak MN. Insulin-like growth factors and neoplasia. Novartis Found Symp. 2004;262:84-98.
10. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4(7):505-518.
11. Surmacz E. Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor. Oncogene. 2003;22(42):6589-6597.
12. Hakam A, Yeatman TJ, Lu L, et al. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol. 1993;30:1128-1133.
13. Kanter-Lewensohn L, Dricu A, Girnita L, et al. Expression of insulin-like growth factor-1 receptor (IGF-1R) and p27Kip1 in melanocytic tumors: a potential regulatory role of IGF-1 pathway in distribution of p27Kip1 between different cyclins. Growth Factors. 2000;17:193-202.
14. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev. 2000;21:215-244.
15. Turner BC, Haffty BG, Narayanan L, et al. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res. 1997;57:3079-3083.
16. Ericsson C, Girnita L, Seregard S, et al. Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. Invest Ophthalmol Vis Sci. 2002;43(1):1-8.
17. Economou MA, All-Ericsson C, Bykov V, et al. Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications. Invest Ophthalmol Vis Sci. 2005;46(12):4372-4375.
18. Kang DC, Motwani M, Fisher PB. Role of the transcription factor AP-1 in melanoma differentiation (review). Int J Oncol. 1998;13(6):1117-1126.
19. Krishnakumar S, Abhyankar D, Lakshmi SA, et al. HLA expression in choroidal melanomas: correlation with clinicopathological features. Curr Eye Res. 2004;28(6):409-416.
20. Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004;64(20):7205-7209.
21. Krishnakumar S, Mallikarjuna K, Desai N, et al. Multidrug resistant proteins: P-glycoprotein and lung resistance protein expression in retinoblastoma. Br J Ophthalmol. 2004;88(12):1521-1526.
22. Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res. 2002;62(1):200-207.
23. Steinbach JP, Eisenmann C, Klumpp A, Weller M. Co-inhibition of epidermal growth factor receptor and type 1 insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis. Biochem Biophys Res Commun. 2004;321(3):524-530.
24. Warshamana-Greene GS, Litz J, Buchdunger E, et al. The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling. Mol Cancer Ther. 2004;3(5):527-535.
25. Lu Y, Zi X, Zhao Y, et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst. 2001;93(24):1852-1857.
26. Camirand A, Lu Y, Pollak M. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med Sci Monit. 2002;8(12):BR521-BR526.